Estimate-busting sales amid Bayer’s mixed bag

6 August 2024

Germany’s Bayer (BAYN: DE) has reported group revenue of 11.1 billion euros ($12.2 billion) in the second quarter of 2024, ahead of the 10.9 billion euros average of analysts’ estimates and up by 1% on the same period a year ago.

The Pharmaceuticals division was a stellar performer, with its sales rising 1% to 4.61 billion euros thanks to growing demand for its new drugs, Nubeqa (darolutamide) for prostate cancer, and the kidney medicine Kerendia (finerenone). The firm’s older eye medicine Eylea (aflibercept) topped estimates with higher sales.

Bayer raised its 2024 sales outlook for the pharma unit. The company now predicts revenue to stay flat or even grow slightly, up from the previous guidance that anticipated declining sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK